Viatris (VTRS) said Wednesday its phase 3 trial in Japan evaluating EFFEXOR for generalized anxiety disorder met its primary objective, showing superiority over placebo in reducing anxiety symptoms at eight weeks.
The trial, which assessed 804 patients, met primary and all secondary efficacy endpoints, Viatris said. EFFEXOR was generally well tolerated, with low discontinuation rates and no severe treatment-emergent adverse events, it added.
Viatris shares were up 0.7% in recent premarket activity.
Price: 11.40, Change: +0.08, Percent Change: +0.71
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.